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SUMMARY 
AIOS-8ssociated Kaposi's sarcoma (KS) in eight patients was treated with the svs-
temic appUcation of liposomal doxorubicin (20 mg/m2 per cycle), After six cycles of 
treatment a significant regression of KS was observed in all patients. Tumour volume 
was reduced trom 556 ± 635 mm 3 before therapy to 42 ± 134 mm3 after therapy as 
determined by ultresonographv of selected tumours. Histological examination r\vealed 
a reductlon of tumour-lika structures end the absence of KS spindie cells in involved 
arees after therapy.ln vitro experiments with KS-derived ceU cultures, which most like-
Iy raprennt tha KS spindie cels, suggastad that liposomal doxorubicin may cause ragres-
sion of KS via two different mechanisms: liI by highly specific inhibition of KS spindia 
cell proliferation and (11) by induction of monocyte chemoattractant protein-1 expres-
sion in KS spindie cells. which mav result in incre8sad recruitmant of phagocytic cells 
(monocytes/macrophagesl into the lesions. A cooperative actten of both mechanisms 
may explain the high afficacy of liposomal doxorubicin in tha treatment of AIDS-KS. 
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Monocyte chemoattractant protetn-l. 
lNTRODUCnON 
Kaposi's sarcoma (KS) is the most common 
tumour associated with the acquired immunodefi-
ciency syndrome (AIDS) and occurs in more than 
25 0)'0 of all reported cases (Haverkos et al., 1985; 
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Safai et al., 1985). Histologically. KS lesions are 
characterized by prominent vascularization and 
numerous spindle-shaped cells. These so-called spin-
dIe cells are considered to be the tumour cells of KS 
(Ackerman and Gottlieb, 1988). 
Various forms of treatment of KS have been 
described. The appropriatc treatment is selectcd ac-
cording to the clinicaI presentation of the disease. 
Small, IocaIly restricted lesions are treated with elec-
trodessication and curettage, cryotherapy, radiother-
apy. electron-beam therapy, or by surgical excision 
(StickJer and Friedman-Kien, 1991). More severe 
forms of the disease, presenting with multiple dis-
seminated. lesions and involvement of visceraJ organs, 
are treated with systemie ehemotherapy (StickJer and 
Friedman-Kien, 1991). Thc agents used include doxo-
rubicin, bleomycin, vinblastine, vineristine and 
etoposide (VP-16), employed either as monothera-
py or in combination (Stickler and Friedman-Kicn, 
1991). Besides chemotherapy, biologic response 
modifiers such as interferon-lI are systemicaJly em-
ployed aecording to the hypo thesis that these agents 
will prevent tbe immunosuppression following com-
bination chemotherapy (Stickler and Friedman-Kien, 
1991). 
Until recently, all forms of systemie therapy of 
KS werc hampered cither by severe side effects 
(ehemotherapy) or by low response rates (biologie 
response modifiers). Progress in chemotherapy was 
obtained by the availability of long-circulating 
"Stea1th" liposomes loaded with doxorubicin. In an 
animaJ model it has been reported that the prolonged 
cireulation time of liposomal doxorubicin accounts 
for the superior therapeutic effectiveness (Vaage el 
0/., 1992). Phannacological data revealed a long plas-
ma half-life, increased accumulation in tumour tis-
sue and a decrease in uptake by tissues such as liver, 
spleen and bone marrow (Vaage er a/., 1992; Papa-
hadjopulos el 01., 1991; Baly el 0/., 1990) . 
Tbe objectives of our study were (i) to determine 
the efficacy of liposomal doxorubicin in the treat-
ment of KS, (ö) to compare tbc histological presen-
talion of KS before and after therapy and (üi) to 
investigate the molecular mechanisms which might 
account for the high efficacy of liposomal doxoru-
bicin in the treatment of KS. 
MATERIALS AND METHODS 
Patients 
Eigbt patients with biopsy-proveD advanced AIDS-KS, 
presenting witb progressive disseminated cutaneous lesions 
AIDS .. acquired immunodeficiency syndrome. 
AIDS-
FIB .. AIDS-derived fibroblast . 
AIDS-
KS - AIDS-a.ssociated KS. 
FOS - foetal bovine serum. 
HSMC - human smooth musde cell . 
including oedema of the face or limbs or oraIlesions, were 
included in Ihis study. Indusion criteria were age 
;<l= 18 years, Kamofsky status> 50 O'J'o, white blood cell 
count> 2,OOO/ tJl, haemoglobin > 10 g/ dl and platelets 
> 50,000/ 1'1. Exclusion criteria were acute opportunistic 
infections, non-Hodgkins lymphoma, systcmic chemother-
apy, radiation of KS within 4 weeks prior 10 entry into the 
triaJ, major psychiatrie illness, cardiac fajlure and anthracy-
dine intolerance. All patients gave wrinen informed con-
sent. The trial was approved by the institutional review 
board of the Medizinische Poliklinik, University of 
Munich, Germany. 
The baseline evaluation consisted of a medical history 
and a physica1 examination. Indicator lesions were evalu-
ated by sonographie measurements of romour volume in 
all patients as described previously (Bogner et 01., 1993a 
and b) . At least one indicator lesion accessible for 
cutaneous ultrasound examination was required ir palients 
presented with oral or visceral lesions. 
Clinica.l assessment and ultrasound measurements were 
performed at the end of each cyde within 48 h before ad-
ministration of the next dose. Overall response was deter-
mined .after six cycles of treatment. 
KS-staging was performed according to the 
tumour/ immune system/ systemic illness (fIS) system as 
published by the AIDS Clinica1 Trials Group (ACTG) 
(Krown et 01., 1989). 
Response criteria were applled as recommended by the 
AcrG (Krown et al., 1989). A complete response (CR) was 
defined as the absence of any detectable residual disease, 
including tumour-associated oedema. In the case of rcmain-
ing macular lesions, a biopsy documenting the histologi-
cal absence of tumour-like structures was required. 
A partial response (PR) was defined as either at least 
a 50 '70 decrease in the sum of the areas of all previously 
existing lesions lasting for at least 4 wecks or at least a 75 % 
decrease in nodularity of alI previously existing lesions. The 
rating of PR was only pennitted if no new skin or oralle-
sions appeared and if KS-related oedema did not worsen. 
Stable disease (SO) was any response not meeting the 
criteria for CR, PR or progressive disease. 
Progressive disease (PD) was deftned as any occurrence 
of new Icsions or the increase of more than 25 0'/0 in the 
size of previously exisling lesions, or the increase of oede-
ma or effusions. 
Treatment scbedule 
Liposomal encapsulated doxorubicin was administered 
intravenously at a dosage of 20 mg/ m I every three weeks 
HUVEC - human umbilical vein endothelial cell. 
KS '" Kaposi's sarcoma. 
KSC .. AIDS-KS-derived cell cuhure. 
MCP-I monocyte ehernoattraetant protein-1. 
N-FlB - normal fibroblast. 
PAS periodic acid and Schiffs rtalent. 
TIS "" tumour/ immune system/ systemic iUness (system). 
at the outpatient dink of the Medizinische Poliklinik. 
University of Munich. German)'. 
Liposomal doxorubiein (SteaJth liposomal doxorubi-
ein) was supplied by Liposome Technology Inc., Menlo 
Park. CA. USA. 
Histologie" prootdures 
Skin punch biopsies were performed for histological 
evaluation of KS lesions. Immediately after removal, 
biopsies were transferred to a solution of freshly prepared 
" '10 paraformaldehyde in phosphate-buffered saline (PBS). 
The procedure for dehydration and paraffin-embedding 
was performed as described by Stürz! et 01. (1992). Subse-
quently, haematoxylin-eosin, elastic van Gieson, PAS and 
prussian blue stained paraffin sections were examined. 
Cell euUure 
AIDS-KS-derived cell cullures (KSC), AIDS-derived 
fibroblasts (AIDS-FIB). normal fibroblasts (N-FIB) and 
human smooth rnusde cells (HSMC) were cultivated as 
described (Roth et 01 .• 1988). The following KSC were used 
in these studies: M7/3, MS/I. M812 and M8col". AIDS-
FIB were derived from an uninvolved area of the skin of 
the patients M7 and M5. N-FIß were derived from a skin 
biopsy of an HIV -negative man. Human umbilical vein en-
dothelial cells (HUVEC) were purchased from Laevo-
san/Vienna and CI.Iltivated according 10 the instructions of 
the supplier. Suspension cultures of the m)'elomonOC}'lic 
ceilline U937 (ATCC. Wakersville, MD) were maintained 
in RPMI-I640 supplemented with IO '10 FBS. 
Prollfention assays 
In order 10 anal)'se the inhibitory effect of liposomal 
doxorubicin on proliferation of cultivated cells, 3 x 10· 
cells of HSMC or 3 x 10' cells of KSC, AIDS-FIß, N-FIB 
and HUVEC were seeded into 24-multiwell plates and cul-
tivated in the appropriate medium supplemented with 10 '10 
FBS for live da)'s (one da)' for HlNEC). After this incu-
bation. all cultures reached confluency with an average cel! 
number of 106 cells/well. Subsequently, cells were washed 
in DMEM and incubated in DMEM/IO OJo FBS with 
various concentrations of liposomal doxorubicin. Non-
adherent U937 cells were seeded with an initial density of 
106 cells/well in RPMI-I640 supplemented with 10 '10 FBS 
and various conccntrations of liposomal doxorubicin. Af-
ter 18 h of incubation with liposomal doxorubicin. 1 "Ci 
lH-thymidine was added to each weil for " h. Finali)', 
cells were harvested. and the incorporated radioactivity was 
determined by scintillation counting. Each experiment was 
carried out in triplicate and reproduced at least twice, The 
mean values were ca1culated. 
RNA prepara(JOD and Northera blol analysis 
Cells were grown to confluency. incubated for thrte 
days in DMEM/IO 010 FBS. Subsequently, the medium 
was replaced by fresh medium. and after 12 h of incu-
batjon, 10 ng/ml Iiposomal doxorubicin was added in 
DMEM/IO OJa FBS er DMEM/O '1/0 FBS. At different time 
points after the addition of liposomal doxorubicin. total 
RNA was isolated using the acid phenol method as 
described (Sambrook et 01 .• 1989). Isolated RNA was sub-
jected to Northern analysis with a cDNA probe which was 
radioactively labelIed using a random priming kit 
(Boehringer, Mannheim). 
RESULTS 
Eight patients were enrolled in a clinical study in 
order to examine the efficacy of Iiposomal doxoru-
bicin in the treatment of AIDS-KS, The mean age 
of the patients was 39.6± 8,5 years. Classification of 
KS according to TlS stages (KIown e/ol,. 1989) was 
Tl (poor risk) and 11 (CD4 count below 2OO/fLI) in 
all patients. and SI (opportunistic infections before 
KS) in 6 patients. Oral and/or gastrointestinal KS 
were present in 6 and 2 patients, respectively. One 
patient had proven pulmonary KS. 
Skin punch biopsies were performed prior to ther-
apy for histological evaluation of KS diagnosis 
(fig. JA). Six cases showed typical histomorpholo-
gical features of the plaque or the late plaque stage 
of KS. Two patients exhibited the criteria of an ear-
l)' nodulae stage of KS. Numerous bizaere-shaped, 
thin-walled vessels (fig. lA, white arrow) and the 
typical KS spindle ceUs (fig. lA, black arrow), which 
were focally arranged in short fascicles, were obvious 
in all sections examined. Tumour volume was 
556±635 ~ (range 22 to 2,204) as determined by 
ultrasonography. 
After six cycles of treatment, the.,average turnour 
volume was reduced to 42 ± 134 jJJ (range 0 to 624; 
p < 0.01, paired / test). Response was rated by the 
criteria mentioned in "Materials and Methods". One 
patient showed complete response; partial response 
was observed in seven patients. No patients showed 
progression or stable disease while on therapy. Le-
sions that, prior to therapy, bad been clinicaUy and 
ultrasonographicaUy proven to be KS plaque or 
nodular stage showed a histological picture complete-
Iy different from that expected in such cases after 
treatment with liposomal doxorubicin. The typical 
KS spindie ceDs were DO longer seen. neither in the 
upper (fig. IB) nor in the deeper part of the epider-
mis (fIg. lC). Especially in the upper third orthe der-
mis, there was a variable number of small vascular 
structures (fig. IB), sometimes resembling an early 
patch KS lesion. In the deeper part of the dermis, 
abundant siderophages were most evident (fig. lC). 
No evidence of necrosis or prominent haemorrhagia 
could be detected in any of the cases. 
Tbe clinical study reported above demonstrated 
the high efficacy of liposomal doxorubicin in the 
treatment of AlDS-KS, Only minor side effects were 
observed in the patients enrolled. In order to inves-
tigate whether the rarity of adverse effects may be 
explained by an increased sensitivity of the KS spin-
die cells to liposomal doxorubicin in companson with 
other ceUs, we performed proliferation assays in vitro 
(fig. 2). In these experiments similar concentrations 
of liposomal doxorubicin were used as were calcu-
lated to be present in the serum of KS patients dur-
ing the treatment (10 ng/ml-l "g/ml). At these 
eoneentrations, proliferation of KS-derived cells, 
whieh exhibit features similar to those of KS spindie 
cells in vivo (Stürzl et 01., 1992), was stongly inhibit-
ed (fig. 2A). Proliferation of endothelial cells 
(fig. 2D), monocytes (fig. 2E) and smooth muscle 
cells (fig. 2F) was c1early inhibited to a lesser extent. 
Qnly the proliferation of fibroblasts which were es-
tablished either from biopsies of an urunvolved area 
of the skin of AJDS-KS patients (fig. 2B) or from 
healthy persons (fig. 2C) was inhibited with equal ef-
ficacy as was the proliferation of KS-derived cells. 
Tbe differenees in growth inhibition were greatest at 
a concentration of 10 ng/ml of liposomal doxorubi-
ein (fig. 3). At this concentration. DNA synthesis of 
KS-derived cells (fig. 3, open square), normal fihro-
blasts (fig. 3, open circle) and AIDS fibroblasts 
(fig. 3, black square) was less than 29.8 % of the 
values obtained from the untreated controls. By con-
trast, DNA synthesis of monocytes (fig. 3, open tri-
angle), human smooth muscle cells (fig. 3, black 
triangle) and human endothelial cells (fig. 3, black 
circle) was still more than 79 % of the untreated con-
trols. The increased inhibitory effect (~ 2.S-fold) of 
Iiposomal doxorubicio 00 DNA synthesis of KS-
derived cells and fibroblasts in comparison with its 
effect on other cell types may be an important rea-
son for the high efficacy of liposomal doxorubicin 
in the treatment of KS. 
Tbe absence of KS spindIe ce1ls after the treatment 
of patients with liposomal doxorubicin, without de-
tectable necrosis, suggested that phagocytotic cells 
(monocytes/maerophages) may be involved in 
tumour regression. Therefore, we examined the ef-
fect of Iiposomal doxorubicin on the expression of 
monocyte chemoattractant protein-l (MCP-l) by 
Northern analysis. lnterestingly, expression of this 
monocyte chemoattractant is strongly induced in KS-
derived cells between 0.5 and 8 h after exposure to 
liposomal doxorubicin in concentrations of 10 ng/ml 
(fig. 4). As shown above, monocytes are less sensi-
tive to Iiposomal doxorubicin than are KS-derived 
cells (fig. 3). Therefore, during treatment of AIDS-
KS with liposomal doxorubicin, monocytes may still 
be able to respond to MCP-I expression of KS eells 
by increased migration into the tumour. Removal of 
eylostatie KS spindie cells by the phagocytotie capa-
bility of monocytes/macrophages may explain the 
absence of the KS spindie eells in KS lesions subse-
quent to treatment with Iiposomal doxorubicin 
(fig. 1). 
D1SCUSSION 
We report on a significant reduction of AIDS~KS 
lesioris in eight patients after treatment with 
liposomal doxorubicin. Subsequent histological exa-
mination of areas where tumour regression was ob-
served revealed an absence of KS spindie cells and 
a significant reduction of tumour-Iike struetures. Ad-
verse effects such as nausea, stomatitis and consti-
pation. which were reported dunng therapy with free 
doxorubicin (Fisch] el 01., 1993), were rare events 
during therapy with liposomal doxorubicin. None of 
the adverse effccts was severe enough to terminate 
chemotherapy in the group of patients reported here. 
This indicates that liposomal doxorubicin is a power-
ful chemotherapeutic agent for the treatment of 
AIDS-KS. 
lncreased pharmacological efficaey of liposomal 
doxorubiein in eomparison with free doxorubicin 
may explain the success of this treatment (Vaage el 
01., 1992; Papahadjopulos et 01., 1991; Bally el 01 .• 
1990). Stealth liposomes, which were used in this 
study, reveal decreased uptake by the mononuclear 
Fi:g. 1. Histological examination of KS lesions before and after treatment with liposomal doxorubicin. 
A) Histologica1 seetion ora KS biopsy berore treatment with liposomal doxorubicin. Within [his 
plaque of KS are an inereased number of relatively small, sometimes dilated, bizarre-shaped, [hin-
walled vessels situated around pre-existing vascular structures in the enlire reticular dermis (white 
arrow). These spaces are lined by inconspicous endothelial eells without atypia, and there are also 
increased numbers of spindIe cells (black arrow), monocytes/histiocytes and plasma cells 
(baematoxylin-eosin stain; magnification x 130). 
Band q Histologica1 seetion of a KS lesion after treatment with liposomal doxorubicin. The 
cbaraeteristic pattern of a KS plaque is no longer seen. Vascular structures, eleft-like spaces and 
spindie ceils are rcduced or absent (8: haematoxylin-eosin stain; magnification x 130). Especially 
in tbc dcepcr part of tbe epidermis. abundant siderophages were seen. No evidence of necrosis or 
pronounced haemorrhagia could be detected (C: iron stain with prussian blue, magnification x 130). 
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Fig.2. Growth inhibition of different cell types by IiposomaJ doxorubidn. 
Cells were grown in 24-multiwell plates until a density of 106 cells/well was reached. Subsequent-
Iy. cells wert: incubated in the respective medium supplemented with 10 '10 FBS and with various 
conoentratiollS of liposomaJ doxorubicin. After an 18-h incubation with liposomal doxorubicin, 1 "Ci 
3H_thymidinc was added to each weil for 4 h. Finally, cells were harvested, and the incarporated 
radioactivity was determined by scintillation counting. Each experiment was carried out in tripli-
cate. Thc mean values were calculated and are shown in the figure. Thc following concentrations 
of liposomal doxorubicin were used: column I = positive contral without liposomal doxorubicin. 
column 2 = 1 "gImi, column 3 z: 100 ng/ml and column 4 = 10 ng/ml. 
HSMC = human smooth muscle cells; HUVEC "" human umbilica1 vein endothelial cells: U937 
= myelomoDocytic cellline. 
• 
• 
pbagocyte system (reticuIoendothelial system), result-
ing in prolonged circulation half-lives of the lipo-
somes in the body in comparison with other 
formulations of liposomes (Allen el al., 1991). The 
high vascularization of KS lesions, in combination 
with an abnormal permeability of capillarics, may 
result in a proportionally bigher liposome deposition 
in twnour tissue as compared with that in other tis-
sues, which is concomitant with increased drug depo-
sition (Vaage et 01., 1992; Rahman et 01., 1990). 
Therefore, lower toxicity was anticipated as comM 
pared with conventional doxorubicin (Fischl et al .• 
1993). 
In addition, we could show in this study that 
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Fig. 3. Comparison of relative proliferation rates of differ· 
ent cell types under various concentrations cf liposomal 
doxorubicin . 
Relative proliferation rates of the respective cell types 
at different concentrations cf IiposomaJ doxorubicin in 
comparison with the untreated contral wert ca1cu]ated. Tbc 
difference in growth inhibition cf the various cell types is 
greatest al a conccntration cf 10 nglml cf liposomal dox-
orubicin. KS-derived cells, open square; normal fibroblasts, 
open circ1e i AIDS fibroblasts, black square; monocytes. 
open triangle ; HSMC, black triangle ; human endothelial 
cells, black cirele. 
liposomal doxorubiein inhibits the proliferation of 
KS-derived ceUs and fibroblasts more efficienUy than 
it inhibits the proliferation of endothelial cells, hu-
man smooth muscle cells and monocytes. Increased 
specificity of liposomal doxorubicin for KS spindie 
cells in comparison with that for other cell types may 
contribute to the fact that only a few adverse effects 
were observed in patients during treatment. The 
difference in growth inhibition was most obvious at 
concentrations of 10 ng/ ml of liposomal doxorubi-
ein, whereas concentrations of I f'g / ml resulted in 
similar inhibition of tbe various cell types . This sug-
gests that treatment with liposomal doxonibiein may 
be even further improved by careful evaluation of 
the optimal concentrations uSed for therapy. 
The strong inhibition of fibroblast proliferation 
suggests that doxorubicin may bave effects on the 
connective tissue. No such effeets have been detect-
ed during histological and clinical follow-up of the 
tberapy. However, it has been shown tbat anthracy-
dines, such as doxorubicin, are subjected to meta-
bolie reduction leading to very reactive free radieals 
(Benchekroun and Robert, 1992). Free radicals cause 
membrane lipid peroxidation or induce breakage of 
tbe DNA backbone, whicb results in inhibition of 
proliferation of eukaryotic ceUs (Bencbekroun and 
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Flg. 4 . Induction of monocyte chemoattractant protein-] 
expression in KS-derived ceUs by liposomal doxorubicin. 
KS-dcrived cells were grown to confluency. incubated 
for thr« days in OMEM/ lO "10 FBS. Subsequently, the 
medium was replaced by fresh medium. After a 12·h incu-
bation, 10 ng/ ml liposomal doxorubicin was added in 
OMEM/ IO "10 FBS, and RNA was isolated after 0, 0.5, 
2, 8 and 24 h. Nonhern blot hybridization wirh a radioac-
tively labelIed cONA probe (specific activity : 
I x 10' cpm/~g DNA) specific for MCP-I reveaJed signifi-
cant induetion of MCP-l expression. Similar results were 
obtained when liposomal doxorubicin was added in 
DMEM/ O "10 FBS (data not shown). An ethidiwn bromide 
stain of the biotted RNA is shown in order to demonstrate 
that equal amounts of RNA were applied. 
Robert, 1992). This indicates tbat the action of 
doxorubicin is dependent on the metabolie activity 
of the target cells. Fibroblasts may have reduced 
metaboüc activity when present in normal tissue in 
vivo, in comparison witb tbe situation in vi/ro which 
leads to permanent stimulation. Reduced metaboüc 
activity in vivo may result in lower doxorubicin sen-
sitivity of fibroblasts . This may explain tbe fact that 
no adverse effeets of liposomal doxorubicin on the 
conneetive tissue were reeognized during treatment 
of patients. 
The histological follow~up of therapeutic regres~ 
sion of KS lesions demonstrated the absence of the 
KS spindie cells in involved areas. Areas where le~ 
sions in a plaque or nodular stage were present be~ 
fore therapy reveaIed either significant reduction or 
complete absence of tumour-like structures. Necro-
sis or pronounced haemorrhagia were not observed. 
The removaI of the KS spindie cells without deteeta-
ble necrosis suggests that, besides the cytostatic ef-
feet of liposomal doxorubicin. further mechanisms 
may be involved in tumour regression during thera-
py. In this eontext two mechanisms can be imagined: 
(i) migration of KS spindie eells out of the lesion and 
(ii) involvement of phagoeyT.es which may contrib-
ute to the removaI of necrotic spindie cells under 
cytoslasis. 
Support for the second mechanism was obtained 
by the observation that liposomaI doxorubicin in con-
centrations of 10 ng/mJ induces the expression of 
monoeyte ehemoattraetant protein-! in KS-derived 
cells. These concentrations of liposomal doxorubi-
ein cause eomplete cyT.ostasis of KS-derived cells, 
whereas monocytes are only marginally affected. 
These data suggest that inereased migration of 
phagocytotic eells (e,g. siderophages) may indeed 
contribute to KS regression during treatment with 
Jiposomal doxorubiein. 
In summary, we provide evidence that KS spin-
die cells are more sensitive than other cells to the 
CyT.ostatic effects of liposomal doxorubicin. Together 
with the increased drug delivery into KS lesions, 
which has been suggested by earlier reports, this find-
ing may explain the high efficacy of liposomal dox-
orubicin in the treatment of AIOS-KS. 
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La doxorubicine en liposomes dans le traitement 
du sarcome de Kaposi lie au SIDA; 
evaluation clinique, histologique 
et biologique ceUulaire 
Huit sujets atteints de sarcome de Kaposi (SK) 
associe au SIDA (SK*SIDA) ont ete traites par des 
liposomes porteurs de doxorubicine, a raison de 
20 mg/m 2/perfusion. Apres 6 perfusions adminis* 
trees a des intervalles de 3 semaines, on observe une 
regression du sarcome chez tous les sujets. Le volume 
tumoraI, evalue par ultrasons, est passe de 556 ±635 
a 42± 134!L1. L'anaIyse histologique revele une 
reduction des structures de type tumoral et une 
absence de cellules SK fusiformes dans les zones 
tumorales en involution apres ce traitement. L'etude 
in vitro, sur des cultures de SK, montre que deux 
mecanismes peuvent ~tre impliques dans I'action 
reductrice de la doxorubicine: (I) une forte inhibi-
tion specifique de Ja proliferation des cellules fusi-
formes et (2) une induction de I'expression de la 
proteine-I chimioattractive monocytaire dans les 
cellules fusiformes du SK, pouvant accroitre Je recru* 
tement des cellules phagocytaires (monocytes/macro-
phages) dans les lesions. Une synergie d'action de ces 
deux. mecanismes peut expliquer la grande efficacite 
de la doxorubieine en liposomes dans Je traitement 
du SK-SIDA. 
Mols*cJes: SIOA, Sarcome de Kaposi, Doxoru-
bicine, Liposome; Traitement, Cellules fusiformes, 
Proteine-) monocytaire. 
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